Global Cholera Vaccines Market By Product Type (Dukoral, Vaxchora, Shanchol, and Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Other), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Cholera Vaccines Market was valued at USD 94.5 million in 2024 and is anticipated to register substantial growth of USD 230.0 million by 2034, with 9.3% CAGR. In 2023, North America led the market, achieving over 38.4% share with a revenue of US$ 36.2 Million.

The cholera vaccines market is driven by rising incidences of cholera outbreaks, increasing awareness of preventive healthcare, and growing government initiatives to control waterborne diseases. The demand for oral cholera vaccines (OCVs) has surged due to their ease of administration and effectiveness in outbreak prevention. Organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance are actively supporting large-scale immunization programs, particularly in cholera-endemic regions of Africa and South Asia.

Additionally, advancements in vaccine development, including longer-lasting immunity and improved formulations, are boosting market growth. However, the market faces challenges such as limited access to vaccines in remote areas, cold chain storage requirements, and vaccine production constraints during high-demand periods. The increasing investment in public health infrastructure and the development of new-generation cholera vaccines present significant opportunities for market expansion.

• According to the National Institutes of Health, as of August 2024, 60,834 new cases and 227 deaths were reported worldwide.

Key Takeaways

• The cholera vaccines market was valued at USD 94.5 million in 2024 and is anticipated to register substantial growth of USD 230.0 million by 2034, with 9.3% CAGR.
• In 2024, the dukoral segment took the lead in the global market, securing 33.4% of the total revenue share.
• The hospital pharmacy segment took the lead in the global market, securing 46.2% of the total revenue share.
• North America took the lead in the global market, securing 38.4% of the total revenue share.

Product Type Analysis

Based on product type the market is fragmented into dukoral, vaxchora, shanchol, and other. Amongst these, dukoral segment dominated the cholera vaccines market capturing a significant market share of 33.4% in 2024.

The Dukoral segment has dominated the cholera vaccines market due to its widespread use in both endemic regions and for traveler immunization. Dukoral, an oral, inactivated cholera vaccine (OCV) developed by Valneva and licensed to Emergent BioSolutions, is widely recommended for individuals traveling to cholera-prone areas, making it a preferred choice in high-risk regions. Its dual protection against cholera and enterotoxigenic Escherichia coli (ETEC)-induced diarrhea further strengthens its market position.

The vaccine’s long-standing regulatory approvals, including endorsements by the World Health Organization (WHO) and other health agencies, have contributed to its market leadership. Additionally, its ease of administration, proven efficacy, and availability in both public health programs and private sectors fuel its dominance. Despite competition from other oral cholera vaccines (OCVs) like Shanchol and Euvichol, Dukoral remains a top choice for travelers and outbreak prevention, reinforcing its stronghold in the global cholera vaccines market.

Distribution Channel Analysis

The market is fragmented by distribution channel into hospital pharmacy, retail pharmacy, and other. Hospital pharmacy dominated the cholera vaccines market capturing a significant market share of 46.2% in 2024. The hospital pharmacy segment has dominated the cholera vaccines market due to its critical role in vaccine distribution, administration, and patient care.

Hospitals serve as primary centers for vaccination programs, outbreak response, and travel immunization services, making them a key distribution channel for cholera vaccines. Given the severity of cholera and its rapid transmission in outbreak-prone regions, hospitals are often the first point of contact for infected individuals and those at risk, ensuring immediate vaccine access.

Additionally, government-backed public health initiatives and immunization drives often rely on hospital pharmacies for vaccine storage, handling, and administration, reinforcing their dominance in the market. Hospital pharmacies also ensure proper cold chain management and adherence to safety protocols, crucial for maintaining vaccine efficacy.

Key Segments Analysis

Product Type

• Dukoral
• Vaxchora
• Shanchol
• Other

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

Market Dynamics

Increasing Incidence of Livestock Diseases

The rising incidence of cholera cases is a key driver of growth in the cholera vaccines market, as increasing outbreaks worldwide necessitate widespread immunization efforts. Cholera, a highly contagious waterborne disease, continues to pose a significant public health threat, particularly in developing regions of Africa, South Asia, and Latin America, where access to clean water and sanitation remains limited. Climate change, urbanization, and natural disasters further exacerbate the spread of cholera by contaminating water sources and increasing the risk of outbreaks.

Market Restraints

High Cost for Drug Development

The high cost of drug development is a significant factor restraining the growth of the cholera vaccines market. Developing new vaccines involves extensive research and development (R&D), clinical trials, regulatory approvals, and manufacturing processes, all of which require substantial financial investment. The lengthy and costly clinical trial phases, particularly for vaccines that need to demonstrate long-term efficacy and safety, further add to the expenses.

Additionally, maintaining a cold chain storage system for vaccine distribution, especially in cholera-endemic regions with poor infrastructure, increases operational costs. Limited commercial profitability discourages many pharmaceutical companies from investing in cholera vaccine development, as the primary demand comes from low-income and developing countries, where governments and health organizations often rely on donor funding.

Market Opportunities

Increasing International Travelling

The increase in international travel is creating a significant growth opportunity for the cholera vaccines market, as more travelers seek protection against waterborne diseases in high-risk regions. With rising global tourism, business travel, and humanitarian missions to cholera-endemic areas in Africa, South Asia, and Latin America, the demand for preventive vaccines is surging. Travelers, including expatriates, aid workers, and military personnel, are required or advised to get vaccinated before visiting regions where cholera outbreaks are prevalent.

Impact of macroeconomic factors / Geopolitical factors

Macroeconomic and geopolitical factors play a crucial role in shaping the cholera vaccines market, influencing production, distribution, and accessibility. Economic conditions, including government healthcare budgets, funding for immunization programs, and investments in public health infrastructure, directly impact vaccine availability, especially in low-income and cholera-endemic regions. International organizations like WHO, Gavi, and UNICEF often step in to provide financial aid, but economic downturns and budget constraints can limit large-scale vaccination efforts.

Geopolitical factors such as conflicts, political instability, and trade restrictions disrupt vaccine supply chains, making it difficult to deliver vaccines to affected regions. Additionally, climate change-induced natural disasters, such as floods and hurricanes, exacerbate cholera outbreaks by contaminating water sources, increasing the urgent demand for vaccines.

Latest Trends

The cholera vaccines market is experiencing significant advancements driven by increasing outbreaks, global immunization efforts, and vaccine production expansions. The rising number of cholera cases, especially in regions with poor sanitation and unsafe drinking water, has intensified demand for oral cholera vaccines (OCVs) such as Shanchol, Euvichol, and Dukoral. To address vaccine shortages, manufacturers such as EuBiologics are ramping up production, while new players like Bharat Biotech are introducing vaccines like Hillchol to expand global access.

Additionally, governments and international health organizations like WHO and Gavi are strengthening vaccination programs to curb outbreaks in endemic regions.

Regional Analysis

North America dominated the cholera vaccines market due to its well-established healthcare infrastructure, high awareness levels, and strong government support for immunization programs. The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) actively recommend cholera vaccination for travelers visiting endemic regions, boosting vaccine demand. Additionally, the presence of leading pharmaceutical companies, advanced research facilities, and continuous investments in vaccine development contribute to the region’s market leadership.

North America’s dominance is also driven by a higher adoption rate of travel vaccines, as many individuals seek protection before visiting cholera-prone areas. Hospital pharmacies, travel clinics, and retail pharmacies play a crucial role in vaccine distribution, ensuring accessibility for travelers and military personnel.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The cholera vaccines market is characterized by a competitive landscape with several key players striving to address the global demand for effective immunization solutions. Major pharmaceutical companies such as Sanofi, GlaxoSmithKline LLC, Astellas Pharma Inc., Pfizer Inc., and Merck & Co. Inc. are prominent in this sector, leveraging their extensive research and development capabilities to innovate and distribute cholera vaccines.

The market is also witnessing contributions from specialized vaccine manufacturers like Valneva SE, known for its oral vaccine Dukoral, and EuBiologics Co. Ltd., which supplies Euvichol to global stockpiles. Collaborative efforts between these companies and international health organizations aim to enhance vaccine accessibility, especially in cholera-endemic regions.

Despite challenges such as production constraints and distribution hurdles, the collective focus on technological advancements and strategic partnerships continues to drive the market forward, addressing the critical need for cholera prevention worldwide.

Top Key Players

• PaxVax Inc.
• EuBiologics Co., Ltd.
• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• Astellas Pharma Inc.
• Incepta Vaccine Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories
• Vabiotech

Recent Developments

• In April 2024, EuBiologics Co., Ltd. announced that its new cholera vaccine, Euvichol-S, had received WHO prequalification and is now available for global distribution. According to UNICEF, the total supply of oral cholera vaccines (OCVs) reached approximately 50 million doses in 2024, up from 38 million doses in 2023. This newly approved vaccine is expected to enable EuBiologics to produce vaccines at a lower cost, thereby increasing availability in cholera-endemic regions.
• In February 2023, Emergent BioSolutions Inc. formed a strategic partnership with Bavarian Nordic, granting the latter rights to the Vaxchora vaccine. As part of the agreement, Bavarian Nordic also acquired Emergent’s manufacturing facility in Bern, Switzerland, along with additional sites in San Diego, California. Additionally, it was announced that approximately 280 Emergent employees would transition to Bavarian Nordic, further strengthening the company’s vaccine production and distribution capabilities.

Report Scope